Chesapeake Capital Corp IL Takes $216,000 Position in Envista Holdings Co. (NYSE:NVST)

Chesapeake Capital Corp IL acquired a new stake in shares of Envista Holdings Co. (NYSE:NVST) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 11,173 shares of the company’s stock, valued at approximately $216,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Huntington National Bank increased its stake in shares of Envista by 97.8% during the 3rd quarter. Huntington National Bank now owns 1,919 shares of the company’s stock valued at $38,000 after acquiring an additional 949 shares during the last quarter. Venturi Wealth Management LLC increased its stake in shares of Envista by 528.4% during the 4th quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company’s stock valued at $38,000 after acquiring an additional 1,638 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Envista by 30.5% during the 4th quarter. GAMMA Investing LLC now owns 2,304 shares of the company’s stock valued at $44,000 after acquiring an additional 538 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. acquired a new position in shares of Envista during the 4th quarter valued at about $53,000. Finally, KBC Group NV increased its stake in shares of Envista by 63.9% during the 4th quarter. KBC Group NV now owns 7,903 shares of the company’s stock valued at $152,000 after acquiring an additional 3,082 shares during the last quarter.

Analysts Set New Price Targets

NVST has been the subject of a number of research analyst reports. New Street Research set a $19.00 price objective on shares of Envista in a research note on Thursday, March 6th. UBS Group decreased their target price on Envista from $23.00 to $21.00 and set a “neutral” rating for the company in a report on Monday, March 10th. Mizuho began coverage on Envista in a report on Wednesday, December 4th. They set an “underperform” rating and a $20.00 target price for the company. JPMorgan Chase & Co. decreased their target price on Envista from $20.00 to $19.00 and set a “neutral” rating for the company in a report on Thursday, March 6th. Finally, Jefferies Financial Group boosted their target price on Envista from $20.00 to $22.00 and gave the stock a “hold” rating in a report on Thursday, January 23rd. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $20.18.

Envista Stock Down 1.6 %

NYSE NVST opened at $16.90 on Wednesday. The stock has a market cap of $2.91 billion, a PE ratio of -2.60, a P/E/G ratio of 1.27 and a beta of 1.33. Envista Holdings Co. has a fifty-two week low of $15.15 and a fifty-two week high of $23.00. The business has a 50 day moving average price of $19.89 and a two-hundred day moving average price of $19.63. The company has a quick ratio of 1.76, a current ratio of 2.04 and a debt-to-equity ratio of 0.44.

Envista (NYSE:NVST) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share for the quarter, topping analysts’ consensus estimates of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. As a group, sell-side analysts predict that Envista Holdings Co. will post 1 EPS for the current fiscal year.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.